Editorial

When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention

Register or Login to View PDF Permissions
Permissions× For commercial reprint and permission enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For non-commercial reprints and permissions enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.
Information image
Average (ratings)
No ratings
Your rating

Disclosure:FM and KH are on the European Cardiology Review editorial board; this did not influence acceptance. All other
authors have no conflicts of interest to declare.

Received:

Accepted:

Published online:

Correspondence Details:Koji Hasegawa, Division of Translational Research, National Hospital Organization Kyoto Medical
Center, 1-1, Mukaihata-cho, Fukakusa, Fushimi-ku, Kyoto 612-8555, Japan. E: koj@kuhp.kyoto-u.ac.jp

Open Access:

This work is open access under the CC-BY-NC 4.0 License which allows users to copy, redistribute and make derivative works for non-commercial purposes, provided the original work is cited correctly.

Sodium–glucose co-transporter (SGLT2) inhibitors were primarily developed as anti-diabetic drugs to increase the excretion of glucose in the urine. However, SGLT2 inhibitors have been reported to have multifactorial effects, such as renal protection and improvement of myocardial energy metabolism and anaemia symptoms, which may exert protection against progression of heart failure beyond their mere diuretic action.

Based on the results of large-scale clinical trials (DAPA-HF, EMPEROR-Reduced), the 2021 European Society of Cardiology heart failure guideline has recommended SGLT2 inhibitors as one of the first-line drugs for treatment of heart failure with reduced ejection fraction (HFrEF) in diabetic and non-diabetic patients.1–3 Furthermore, in heart failure with preserved ejection fraction (HFpEF; left ventricular ejection fraction [LVEF] >40%), empagliflozin and dapagliflozin were recently shown to significantly reduce the combined endpoint of cardiovascular death and hospitalisation for heart failure in the EMPEROR-Preserved and DELIVER trials, respectively.4,5 The benefit of these drugs was mainly seen in reducing hospitalisation due to worsening heart failure. Although there were slight differences in the enrolment criteria for the EMPEROR-Preserved and DELIVER trials, the patients’ backgrounds in both trials were similar.4,5 However, the ratio of patients with New York Heart Association (NYHA) III/IV was higher in the DELIVER trial than in the EMPEROR-Preserved trial (NYHA III/IV: 25% in DELIVER versus 18% in EMPEROR-Preserved), and the ratio of patients with loop diuretics use was higher in the DELIVER trial (77%) than in the EMPEROR-Preserved trial (68%). Therefore, a possibility exists of slightly more serious cases being enrolled in the DELIVER trial.

The PARAGON-HF trial, which investigated the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) for HFpEF, showed no efficacy of ARNI in the group with LVEF above the median (ejection fraction >57%).6,7 Unlike the PARAGON-HF trial, an integrated analysis of the EMPEROR-Preserved and DELIVER trials showed a significant reduction in cardiovascular death and hospitalisation for heart failure with SGLT2 inhibitors in the normal LVEF group (≥60%), as well as in the low LVEF group (<60%), and the efficacy of SGLT2 inhibitors was consistent regardless of LVEF.8

SGLT2 inhibitors have been shown to be effective in a broad spectrum of heart failure patients. The question arises, then: at what time point should we begin prescribing these drugs?

A secondary analysis of the DELIVER trial revealed a reduction in cardiovascular death and worsening heart failure soon after the initiation of the drug.9 The results of an integrated analysis of four trials on SGLT2 inhibitors for treatment of HFrEF and HFpEF suggest that the efficacy of SGLT2 inhibitors may decrease in patients with heart failure with severe symptoms (NYHA III/IV) compared to those with NYHA II (interaction p=0.015).5 Regarding the acute phase of heart failure, the early initiation of SGLT2 inhibitors was shown to have few side effects and interactions, and it was easy to find the correct dose.10,11

A randomised, double-blind, placebo-controlled, multicentre trial, which evaluates the efficacy and safety of initiating empagliflozin in the acute phase before clinical stabilisation in high-risk patients with acute heart failure, is currently ongoing.12 Furthermore, a large-scale randomised controlled trial showed that SGLT2 inhibitors reduced new-onset heart failure in patients with pre-heart failure.13

Considering these results, SGLT2 inhibitors are beneficial across the entire spectrum of heart failure; from prevention of worsening chronic heart failure to improvement of acute heart failure. The benefits may be more significant if treatment with SGLT2 is started during the early stages of heart failure rather than in the more advanced stages. Therefore, these drugs should be administered as soon as heart failure symptoms have developed, even if patients are in a stable state. To prevent the progression and worsening of this condition, it is necessary to raise awareness about the need to introduce SGLT2 inhibitors in the early stages of heart failure.

References

  1. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019;381:1995–2008.
    Crossref | PubMed
  2. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 2020;383:1413–24.
    Crossref | PubMed
  3. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599–726.
    Crossref | PubMed
  4. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med 2021;385:1451–61.
    Crossref | PubMed
  5. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med 2022;387:1089–98.
    Crossref | PubMed
  6. Packer M, Zannad F, Anker SD. Heart failure and a preserved ejection fraction: a side-by-side examination of the PARAGON-HF and EMPEROR-Preserved trials. Circulation 2021;144:1193–5.
    Crossref | PubMed
  7. Hasegawa K, Lewis BS. Are SGLT2 inhibitors effective against ‘all’ heart failure with preserved ejection fraction? Eur Heart J Cardiovasc Pharmacother 2022;8:e10.
    Crossref | PubMed
  8. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet 2022;400:757–67.
    Crossref | PubMed
  9. Vaduganathan M, Claggett BL, Jhund P, et al. Time to clinical benefit of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified secondary analysis of the DELIVER randomized clinical trial. JAMA Cardiol 2022;7:1259–63.
    Crossref | PubMed
  10. Voors AA, Angermann CE, Teerlink JR, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 2022;28:568–74.
    Crossref | PubMed
  11. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 2021;384:117–28.
    Crossref | PubMed
  12. Horiuchi Y, Matsue Y, Nogi K, et al. Early treatment with a sodium-glucose co-transporter 2 inhibitor in high-risk patients with acute heart failure: rationale for and design of the EMPA-AHF trial. Am Heart J 2023;257:85–92.
    Crossref | PubMed
  13. McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol 2021;6:148–58.
    Crossref | PubMed